genetically changed CD19-specific autologous T-cell therapy (MD Anderson)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Namegenetically changed CD19-specific autologous T-cell therapy (MD Anderson)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionB-lymphocyte antigen CD19 modulators
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsLymphoma, B-CellLeukemiaMycoses
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesThe University Of Texas MD Anderson Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesThe University Of Texas MD Anderson Cancer Center
Inactive CompaniesN/A
Active IndicationsLymphoma, B-CellLeukemia
Inactive IndicationsMycoses

Other Information

ATC CodeN/A
Related LinksN/A